{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:12:11Z","timestamp":1772770331192,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"OXiGENE, Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vph.2015.05.004","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T18:00:50Z","timestamp":1431799250000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem"],"prefix":"10.1016","volume":"74","author":[{"given":"Qingen","family":"Ke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Samad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soochan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.05.004_bb0005","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/0006-2952(83)90163-6","article-title":"Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin","volume":"32","author":"Hamel","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0010","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/jm0205797","article-title":"Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41","volume":"48","author":"Pettit","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.vph.2015.05.004_bb0015","first-page":"522","article-title":"Current development status of small-molecule vascular disrupting agents","volume":"7","author":"Chaplin","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.vph.2015.05.004_bb0020","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/1078-0432.CCR-09-0035","article-title":"A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas","volume":"15","author":"Meyer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.bjc.6605650","article-title":"A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer","volume":"102","author":"Rustin","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vph.2015.05.004_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1517\/13543780802691068","article-title":"A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)","volume":"18","author":"Siemann","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.vph.2015.05.004_bb0035","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdq708","article-title":"Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer","volume":"22","author":"Zweifel","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0040","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-11-3376","article-title":"Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer","volume":"18","author":"Nathan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2013.0078","article-title":"Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma","volume":"24","author":"Sosa","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.vph.2015.05.004_bb0050","first-page":"717","article-title":"The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses","volume":"21","author":"Prise","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0055","first-page":"1626","article-title":"Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues","volume":"59","author":"Tozer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.vph.2009.08.004","article-title":"Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats","volume":"51","author":"Ke","year":"2009","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejphar.2012.08.023","article-title":"The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries","volume":"695","author":"Su","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vph.2010.10.002","article-title":"Combretastatin-induced hypertension and the consequences for its combination with other therapies","volume":"54","author":"Busk","year":"2011","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0075","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2003.05.186","article-title":"Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate","volume":"21","author":"Anderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0080","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2003.05.187","article-title":"Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging","volume":"21","author":"Galbraith","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0085","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1078-0432.CCR-0364-3","article-title":"Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer","volume":"10","author":"Cooney","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/annonc\/mdr332","article-title":"Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck","volume":"23","author":"Ng","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.critrevonc.2011.01.009","article-title":"Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists","volume":"80","author":"Ederhy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.vph.2015.05.004_bb0105","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"Bodyak","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2015.05.004_bb0110","first-page":"H72","article-title":"Alterations in apoptosis regulatory factors during hypertrophy and heart failure","volume":"287","author":"Kang","year":"2004","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.05.004_bb0115","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.yjmcc.2007.01.001","article-title":"Response of caspase-independent apoptotic factors to high salt diet-induced heart failure","volume":"42","author":"Siu","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.vph.2015.05.004_bb0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1152\/physiolgenomics.00226.2004","article-title":"Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats","volume":"21","author":"Kong","year":"2005","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.vph.2015.05.004_bb0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00610053","article-title":"Pharmacokinetics of diltiazem after intravenous and oral administration","volume":"24","author":"Hermann","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-012-0212-2","article-title":"A review on various targeted anticancer therapies","volume":"7","author":"Li","year":"2012","journal-title":"Target Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0135","first-page":"93","article-title":"Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo","volume":"21","author":"Galbraith","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0140","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6692174","article-title":"In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug","volume":"81","author":"Grosios","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vph.2015.05.004_bb0145","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1111\/bph.12817","article-title":"An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate","volume":"171","author":"Williams","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2015.05.004_bb0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","article-title":"The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents","volume":"37","author":"Siemann","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.vph.2015.05.004_bb0155","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-07-2011","article-title":"Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors","volume":"68","author":"Tozer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.vph.2015.05.004_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7150\/jca.5635","article-title":"Small molecule sequential dual-targeting theragnostic strategy (SMSDTTS): from preclinical experiments towards possible clinical anticancer applications","volume":"4","author":"Li","year":"2013","journal-title":"J Cancer"},{"key":"10.1016\/j.vph.2015.05.004_bb0165","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0170","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1021\/jm0512903","article-title":"Medicinal chemistry of combretastatin A4: present and future directions","volume":"49","author":"Tron","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.vph.2015.05.004_bb0175","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/djm202","article-title":"Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats","volume":"99","author":"Gould","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vph.2015.05.004_bb0180","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vph.2015.05.004_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(97)00122-7","article-title":"Endothelial function as a determinant of vascular function and structure: a new therapeutic target","volume":"79","author":"Gibbons","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2015.05.004_bb0190","doi-asserted-by":"crossref","first-page":"C1764","DOI":"10.1152\/ajpcell.1997.273.5.C1764","article-title":"Regulation of endothelin-1 gene expression by cell shape and the microfilament network in vascular endothelium","volume":"273","author":"Malek","year":"1997","journal-title":"Am J Physiol"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T08:15:50Z","timestamp":1531728950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":38,"alternative-id":["S1537189115001068"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.05.004","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}